Featured Research

from universities, journals, and other organizations

Cancer Drug Extends Cognitive Function In Patients With Brain Metastases

Date:
June 5, 2006
Source:
University of Texas at Austin
Summary:
The drug Xcytrin, based on a molecule developed by chemists at The University of Texas at Austin, shows significant promise in prolonging cognitive function in patients with non-small cell lung cancer that has metastasized to the brain.

The drug Xcytrinฎ, based on a molecule developed by chemists at The University of Texas at Austin, shows significant promise in prolonging cognitive function in patients with non-small cell lung cancer that has metastasized to the brain.

Related Articles


This result, presented at the annual meeting of the American Society of Clinical Oncology on June 5, supports Pharmacylics, Inc.'s recent decision to file a New Drug Application with the U.S. Food and Drug Administration.

In a Phase 3 trial, Xcytrin was delivered in conjunction with whole brain radiation treatment to patients with non-small cell lung cancer that had spread to the brain. Xcytrin significantly prolonged the time to neurologic progression, which is described as a change in mental status, vision and muscle strength associated with the progression of brain cancers.

"In conjunction with radiation, Xcytrin enhances cancer cell death," said Dr. Jonathan Sessler, professor of chemistry and biochemistry and co-founder of Pharmacyclics (Sunnyvale, Calif., PCYC). "Radiation puts stress on the cells and the drug puts further stress on the cells. Add them together and the cells start to die."

More than 500 patients from North America, France and Australia participated in this Pharmacyclics trial combining Xcytrin injection with whole brain radiation. In North America, patients receiving the treatment experienced neurologic progression 16 months later than patients not receiving the treatment.

Xcytrin (motexafin gadolinium) is based on texaphyrin molecules developed in Sessler's lab. Texaphyrins are large, "Texas-sized" versions of porphyrins, which are highly pigmented molecules responsible for the color of red blood cells. Texaphyrins localize to cancer cells and disrupt cellular metabolism and energy production, weakening or destroying the cells. The molecules are relatively non-toxic to normal cells.

Sessler's texaphyrins were designed to hold heavy metals like gadolinium, commonly used to produce magnetic resonance imaging (MRI) agents. As a consequence, Xcytrin allows tumors to be visualized through MRI. The ability to both detect and treat brain and other cancers using the same agent could prove advantageous in a clinical setting, which Pharmacyclics and its collaborators are studying in the context of ongoing early stage clinical trials. Other trials are now underway to test the potential of Xcytrin to act as a stand-alone chemotherapeutic agent or in combination with other known cancer drugs.


Story Source:

The above story is based on materials provided by University of Texas at Austin. Note: Materials may be edited for content and length.


Cite This Page:

University of Texas at Austin. "Cancer Drug Extends Cognitive Function In Patients With Brain Metastases." ScienceDaily. ScienceDaily, 5 June 2006. <www.sciencedaily.com/releases/2006/06/060605121004.htm>.
University of Texas at Austin. (2006, June 5). Cancer Drug Extends Cognitive Function In Patients With Brain Metastases. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2006/06/060605121004.htm
University of Texas at Austin. "Cancer Drug Extends Cognitive Function In Patients With Brain Metastases." ScienceDaily. www.sciencedaily.com/releases/2006/06/060605121004.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Fauci Says Ebola Risk in US "essentially Zero"

Fauci Says Ebola Risk in US "essentially Zero"

AP (Oct. 30, 2014) — NIAID Director Anthony Fauci said the risk of Ebola becoming an epidemic in the U.S. is essentially zero Thursday at the Washington Ideas Forum. He also said an Ebola vaccine will be tested in West Africa in the next few months. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Nurse Defies Ebola Quarantine With Bike Ride

Nurse Defies Ebola Quarantine With Bike Ride

AP (Oct. 30, 2014) — A nurse who vowed to defy Maine's voluntary quarantine for health care workers who treated Ebola patients followed through on her promise Thursday, leaving her home for an hour-long bike ride. (Oct. 30) Video provided by AP
Powered by NewsLook.com
Pot-Infused Edibles Raise Concerns in Colorado

Pot-Infused Edibles Raise Concerns in Colorado

AFP (Oct. 30, 2014) — Colorado may have legalized marijuana for recreational use, but the debate around the decision still continues, with a recent - failed - attempt to ban cannabis-infused edibles. Duration: 01:53 Video provided by AFP
Powered by NewsLook.com
British Navy Ship Arrives in Sierra Leone With Ebola Aid

British Navy Ship Arrives in Sierra Leone With Ebola Aid

AFP (Oct. 30, 2014) — The British ship RFA ARGUS arrived in Sierra Leone to deliver supplies and equipment to help the fight against Ebola. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins